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Abstract 
Review on CDH3, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: CDHP, HJMD, PCAD 
HGNC (Hugo): CDH3 
Location: 16q22.1 
DNA/RNA 
Description 
DNA contains 54807 bp containing 16 coding 
exons. 
Transcription 
4276 bp mRNA transcribed in centromeric to 
telomeric orientation; 2490 bp open reading frame  
 
(CCDS10868.1).  
Concerning CDH3/P-cadherin gene regulation, the 
main transcriptional activators described for the 
CDH3/P-cadherin gene promoter are β-catenin 
(Faraldo et al., 2007), p63 (Shimomura et al., 2008) 
and C/EBPβ (Albergaria et al., 2010; Albergaria et 
al., 2013).  
In contrast, BRCA1/c-Myc/Sp1 complex acts as a 
transcriptional repressor of the CDH3 promoter 
(Gorski et al., 2009).  
It was also demonstrated that ER can indirectly 
repress P-cadherin expression by promoting 
epigenetic changes in the CDH3 gene promoter 
(Paredes et al., 2004; Albergaria et al., 2010). 
This gene has 12 transcripts (splice variants), of 
which 5 are protein coding transcripts, 4 are 
transcripts suffering nonsense mediated decay, and 
3 transcripts do not code for any protein product 
(ensemble ENSG00000062038 and vega genome 
OTTHUMG00000137560). 
 
Localization of CDH3 gene (P-cadherin). 5 cadherin genes (CDH1; CDH3; CDH5; CDH8; and CDH11) are clustered in the 
16q21-q22.1 region. The CDH3 gene is localized in the larger arm of chromosome 16, just 32Kb upstream of the gene encoding 
CDH1 (E-cadherin) (Bussemakers et al., 1994; Kremmidiotis et al., 1998). 
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The genomic structure of the CDH3/P-cadherin gene is constituted by 16 coding exons (NCBI Reference Sequence: 
NM_001793.4): the extracellular part of P-cadherin is encoded by 10 exons (exons 4-13), whereas the transmembrane and the 
intracellular domains are codified by the last 3 exons (exons 14-16) (Albergaria et al., 2011) (NCBI Reference Sequence: 
NM_001793.4). 
 
Protein 
 
Image of a classical type I cadherin, adapted with 
permission from the RCSB PDB March 2008 Molecule of 
the Month feature by David Goodsell (doi: 
10.2210/rcsb_pdb/mom_2008_3). P-cadherin is a 
transmembrane protein included in the classical cadherin 
family, with an ectodomain containing 5 cadherin repeats 
(which interacts with another cadherin's ectodomain in a cis 
or trans manner) and a highly conserved cytoplasmic 
domain that binds to catenins. Sharing about 67% of 
homology with the CDH1/E-cadherin gene, P-cadherin 
differs mainly in the extracellular portion and it is far less 
characterized. 
Description 
Described for the first time in 1986, as "a novel 
class of cadherin that appeared in developing mouse 
embryos", this adhesion molecule was found in the 
tissues that gave rise to its name, the placenta (Nose 
and Takeichi, 1986). P-cadherin is a transmembrane 
glycoprotein that belongs to a large family of 
molecules that mediate calcium-dependent 
homophilic cell-cell adhesion. It plays a role in 
many cellular processes such as embryonic 
development, differentiation, cell polarity, growth 
and migration (Larue et al., 1996). 
P-cadherin is composed by three domains: 1) an 
extracellular portion responsible for calcium-
dependent homotypic cadherin-cadherin interaction 
(which has 5 repeated cadherin domains); 2) a 
single pass transmembrane domain; and 3) a highly 
conserved cytoplasmic domain that binds to the 
intracellular catenins p120-catenin and β-catenin. 
Catenins have a dual role, acting as signalling 
mediators or as adaptor molecules that stabilize the 
cadherin complex at the membrane and link the 
cadherin molecule to the actin filaments of the 
cytoskeleton (Wheelock et al., 2001). 
Expression 
It is expressed in the placenta of mice (hence, its 
name). It is also expressed in human placental 
tissues, albeit at lower levels (Shimoyama et al., 
1989; Sahin et al., 2014). 
Despite being expressed in several human fetal 
structures, in the adult it is only expressed in certain 
tissues, usually co-expressed with E-cadherin, such 
as the basal layer of the epidermis, the breast and 
the prostate, as well as the mesothelium, the ovary, 
the hair follicle, and the corneal endothelium (Nose 
and Takeichi, 1986; Imai et al., 2008). 
According to human protein reference database 
(HPRD:00227), the major sites of expression 
include endometrium, the glomerulus, hair follicle, 
keratinocytes, mammary myoepithelium, 
melanocytes, oocytes, spermatozoa, placenta, 
prostate, retina, serum, skin. An 80 KDa fragment 
of P-cadherin (known as soluble P-cadherin) is also 
found in human breast milk (Soler et al., 2002), 
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nipple aspirates (Mannello et al., 2008), semen (De 
Paul et al., 2005) and urine (Adachi et al., 2006). 
Localisation 
Cell junctions: a single-pass type I membrane 
protein anchored to actin microfilaments through 
association with α-catenin, β-catenin and γ-catenin. 
Sequential proteolysis induced by apoptosis or 
calcium influx, results in translocation from sites of 
cell-cell contact to the cytoplasm. 
Function 
Cell-cell adhesion: cadherin mediated cell-cell 
adhesion is accomplished by homophilic 
interactions between two cadherin molecules at the 
surface of the respective cells in a cis and/or trans 
manner (Cavallaro and Dejana, 2011) and the 
cadherin-catenin complex constitutes the main 
building block of the adherens-type junctions. 
These complexes also represent a major regulatory 
mechanism that guides cell fate decisions, 
influencing cell growth, differentiation, cell 
motility and survival (Cavallaro and Dejana, 2011). 
Cell signalling: P-cadherin shares common 
interplayers with the wnt signalling pathway (eg. : 
β-catenin) (Kamposioras et al., 2013; Samuelov et 
al., 2013) and Integrin signalling (Vieira et al., 
2014). In cancer, it may have a tumour suppressive 
or a cancer promoting function, depending on the 
cellular and tissue context (see below). 
Homology 
Sharing about 67% of homology with the CDH1/E-
cadherin gene, P-cadherin differs mainly in the 
extracellular portion and it is far less characterized. 
64 organisms have orthologs with the human CDH3 
gene. For example, the CDH3 gene is conserved in 
chimpanzee, dog, cow, mouse, rat and chicken 
(HomoloGene:20425). 
Mutations 
Note 
According to the Human Gene Mutation Database, 
21 mutations have been described for the P-
cadherin/CDH3 gene, namely 9 missense/nonsense 
mutations, 4 splicing mutations, 1 regulatory 
mutation, 1 gross deletion, 5 small deletions and 1 
small insertion (The Human Gene Mutation 
Database). There are no reported descriptions of 
small indels, gross insertions/duplications, complex 
rearrangements or repeat variations. 16 mutations 
are associated with Hypotricosis with Juvenile 
Macular Dystrophy (HJMD) and 2 mutations are 
implicated with Ectodermal dysplasia, Ectrodactyly 
and Macular dystrophy (EEM) syndrome (The 
Human Gene Mutation Database). 
Regarding polymorphisms, several SNPs have been 
reported for the CDH3 gene that have no clinical 
significance because they code for synonymous 
codons or related residues (ClinVar). 
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Summary of the human CDH3 gene mutations. 21 mutations have been described for the P-cadherin/CDH3 gene, namely 9 
missense/nonsense mutations, 4 splicing mutations, 1 regulatory mutation, 5 small deletions, 1 small insertion and 1 gross 
deletion (The Human Gene Mutation Database). 
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Germinal 
Human germline mutations for the CDH3 gene 
have been reported to carry the phenotype of HJMD 
and EEM syndromes (Sprecher et al., 2001;Kjaer et 
al., 2005; Avitan-Hersh et al., 2012; Halford et al., 
2012).  
The germline deletion of CDH3 in the mouse 
causes breast secretory immaturity and premature 
mammary gland differentiation.  
The P-cadherin mutant mice develop hyperplasia 
and dysplasia of the mammary epithelium with age 
and, in contrast to humans, no reports regarding 
development defects have been described (Radice 
et al., 1997). 
Implicated in 
Various cancers 
Note 
P-cadherin is altered in various human tumours, but 
its effective role in the carcinogenesis process 
remains object of debate, since it can behave 
differently depending on the studied tumour cell 
model and context.  
For example, in melanoma, P-cadherin seems to 
have a tumour suppressive function, exactly as E-
cadherin (Van Marck et al., 2005).  
In breast cancer P-cadherin is often overexpressed 
and it is reported to exhibit tumour promoting 
effects (Paredes et al., 2012).  
Importantly, P-cadherin upregulation is also found 
in other malignancies such as gastric, endometrial, 
colorectal and pancreatic carcinomas (Hardy et al., 
2002; Stefansson et al., 2004; Taniuchi et al., 2005; 
Imai et al., 2008). 
Breast cancer 
Note 
P-cadherin aberrant expression is found in 20% to 
40% of invasive breast carcinomas, as well as in 
25% of pre-invasive (in situ) ductal carcinomas. 
Aberrant P-cadherin expression was shown to be 
associated with tumours of high histological grade, 
as well as with well established markers of poor 
prognosis, like Ki-67, EGFR, CK5, vimentin, p53 
and HER-2 expression, and negatively associated 
with age at prognosis and hormonal receptors (ER 
and PgR) expression.  
None of these reports showed a significant 
association with tumour size and lymph node 
metastasis (Turashvili et al., 2011; Peralta Soler et 
al., 1999; Gamallo et al., 2001; Paredes et al., 2002; 
Paredes et al., 2005).  
P-cadherin aggressive behaviour in breast cancer is 
dependent on an E-cadherin positive background 
(Ribeiro et al., 2013) and it is substantially 
attributed to an increased migratory and invasive 
capacity of cancer cells (Ribeiro et al., 2010), 
increased stem cell activity (Vieira et al., 2012) and 
cross-talk with integrin oncogenic signalling 
pathways (Vieira et al., 2014). 
P-cadherin up-regulation is predominantly found in 
the basal-like subgroup of breast cancers (Matos et 
al., 2005; Paredes et al., 2007a; Paredes et al., 
2007b) and it is strongly associated with the 
presence of BRCA1 mutation (Arnes et al., 2005) 
and poor clinical outcome (Paredes et al., 2005; 
Turashvili et al., 2011). It has been proposed that P-
cadherin in conjugation with vimentin and CK14 
constitutes a better criterion for the identification of 
basal-like breast carcinomas by 
immunohistochemistry (Sousa et al., 2010). 
Prognosis 
P-cadherin overexpression in breast cancer is an 
independent factor of poor prognosis (poor disease 
free and overall survival) (Paredes et al., 2005; 
Turashvili et al., 2011). 
Hypotrichosis with juvenile macular 
dystrophy (HJMD) 
Note 
In humans, the loss of P-cadherin induces 
characteristic genetic syndromes.  
CDH3 gene mutations have been shown to cause P-
cadherin functional inactivation, leading to 
developmental defects associated with 
hypotrichosis with juvenile macular dystrophy 
(HJMD) (Sprecher et al., 2001; Avitan-Hersh et al., 
2012; Halford et al., 2012). 
Disease 
Hypotrichosis with juvenile macular dystrophy 
(HJMD; OMIM: 601553) is a rare recessive 
disorder, characterized by hair loss heralding 
progressive macular degeneration and early 
blindness. Affected HJMD individuals are born 
with seemingly normal hair but develop alopecia of 
the scalp at around 3 months. After the age of 3 
years, affected individuals develop progressive 
macular degeneration with slight peripheral retinal 
dystrophy. The severe degenerative changes of the 
retinal macula culminate in blindness during the 
second to third decade of life. Since Sprech er et al. 
(2001) first established a link between this disease 
and a mutation in gene encoding CDH3/P-cadherin 
(Sprecher et al., 2001), several other mutations 
were found, which essentially disturb the Ca2+ 
binding and the cadherin functional domains or 
result in the synthesis of a truncated form of P-
cadherin or in the absence of P-cadherin expression. 
Cytogenetics 
The following allelic variants are responsible for 
HJMD: 
- CDH3, c981delG - (Sprecher et al., 2001) 
- CDH3, Arg503His - (Indelman et al., 2002) 
- CDH3, Leu168Term - (Indelman et al., 2003) 
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- CDH3, Arg221Term - (Indelman et al., 2007) 
- CDH3, Tyr249Term - (Avitan-Hersh et al., 2012) 
- CDH3, Glu504Lys - (Indelman et al., 2007) 
- CDH3, His575Arg - (Indelman et al., 2007) 
- CDH3, Tyr615Term - (Indelman et al., 2005) 
- CDH3, IVS2 ds G-A +1 - (Indelman et al., 2007) 
- CDH3, IVS10 as G-A -1 - (Jelani et al., 2009; 
Kamran-ul-Hassan Naqvi et al., 2010) 
- CDH3, IVS12 as A-G -2 - (Shimomura et al., 
2010) 
- CDH3, c.462delT - (Indelman et al., 2003) 
- CDH3, c.2117delG - (Indelman et al., 2003) 
- CDH3, gDNA 8815bp deleted incl exons 12-13 - 
(Halford et al., 2012) 
Ectodermal dysplasia, ectrodactyly 
and macular dystrophy (EEM) 
Note 
CDH3 gene mutations have been shown to cause P-
cadherin functional inactivation, leading to 
ectodermal dysplasia, ectrodactyly, and macular 
dystrophy (EEM syndrome ), a developmental 
defect associated syndrome. This inherited disease 
is characterized by sparse hair and macular 
dystrophy of the retina, and split hand/foot 
malformation (Kjaer et al., 2005). 
Disease 
This ectodermal defect is characterised by 
hypotrichosis with sparse and short hair on the 
scalp, sparse and short eyebrows and eyelashes, and 
partial anodontia. Different degrees of absence 
deformities as well as syndactyly have been 
described, the hands often being more severely 
affected than the feet. The retinal lesion appears as 
a central geographic atrophy of the retinal pigment 
epithelium and choriocapillary layer of the macular 
area with coarse hyperpigmentations and sparing of 
the larger choroidal vessels. 
Kjaer et al. (2005) first established a link between 
families with ectodermal dysplasia, ectrodactyly, 
and macular dystrophy (EEM; OMIM: 225280) and 
homozygous mutations in CDH3/P-cadherin in 
affected individuals: a missense mutation 
(114021.0003) and a deletion (114021.0004), 
respectively (Kjaer et al., 2005). 
Cytogenetics 
The following allelic variants are responsible for 
EEM: 
- CDH3, Asn322Ile - (Kjaer et al., 2005) 
- CDH3, c.829delG - (Kjaer et al., 2005) 
- CDH3, Gly277Val - (Basel-Vanagaite et al., 
2010) 
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